Condition
HIE - Hypoxic - Ischemic Encephalopathy
Total Trials
6
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 6 trials
Late-Stage Pipeline
33%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 3 (1)
P 4 (1)
Trial Status
Recruiting3
Not Yet Recruiting2
Unknown1
Clinical Trials (6)
Showing 6 of 6 trials
NCT07652801Phase 3Not Yet RecruitingPrimary
COMPARISON OF OUTCOME OF HYPOXIC ISCHEMIC ENCEPHLOPATHY MANAGED WITH COMBINATION OF MAGNESIUM SULPHATE AND MELATONIN VERSUS MAGNESIUM SULPHATE ALONE
NCT06857539Recruiting
Assessing Intellectual and Motor Outcomes in High-risk Infants
NCT07413900RecruitingPrimary
Biomarkers Study in Infants With Prior Neonatal Brain Injury
NCT07284498Phase 4Not Yet Recruiting
Treatment of Seizures in Neonate With HIE
NCT07136636RecruitingPrimary
Speech of Kids After Neonatal Encephalopathy
NCT04728438Unknown
Effect of Targeted Temperature Management on Cerebral Autoregulation in Patients With Neurocritical Diseases
Showing all 6 trials